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Prophylactic antibiotic therapy is associated with 
an increased prevalence of Aspergihs colonization 
in adult cystic fibrosis patients 
J. BARGON”, N. DAULETBAEV*, B. K~HLER*, M. WOLF*, H.-G. POSSELT~ 
AND T. 0. F. WAGNER* 
“Division of Pulmonary Medicine, Department of Internal Medicine II and ‘Department of Pediatric Medicine, 
Frankfurt University Hospital, Frankfurt/Main, Germany 
Aspevgillus colonization is a common phenomenon in adult cystic fibrosis (CF) patients. The clinical significance of 
Aspergillus for the pathogenesis of CF lung disease remains unclear and factors predisposing to such colonization 
are still completely unknown. 
We investigated the prevalence of Aspergillus colonization in 104 adult CF patients who attended our outpatient 
clinic in 1997. With respect to demographic and clinical data, and antibiotic therapy received, we further examined 
which factors were associated with Aspergillus colonization in these patients. 
Repeated investigations of CF sputum samples revealed Aspergillus species in 43/104 (41.3%; 95% confidence 
interval 30.2-52.5%) of the patients. We found no significant relationship between Aspergillus colonization and age 
(P> 0,4), gender (P = 0.4), colonization with pseudomonas species (P> 0.6), lower lung function values (P> 0.9), 
or worse chest radiography (P> 0.1). Surprisingly, the prevalence of Aspergillus colonization was higher in CF 
patients receiving prophylactic antibiotic therapy (oral antibiotics: P = 0.05; inhalative antibiotics: P = 0.035; 
both antibiotics: P = 0.048). 
Prophylactic antibiotics are widely used to eradicate or decrease chronic bronchopulmonary infection in CF. Our 
results indicate that long-term antibiotic therapy may predispose CF patients to Aspergillus colonization. 
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Introduction 
Chronic bronchopulmonary infection leads to progressive 
lung destruction in patients with cystic fibrosis (CF). In 
adult patients, the most common pathogen is Pseudomonas 
aeuuginosa. Aspevgillus species are isolated from respiratory 
tract secretions of many CF patients; the prevalence 
reported varies from 25S60% (l-3). Aspergillus infection is 
rarely invasive; however, in approximately 10% of the CF 
population Aspergillus recovery is associated with allergic 
bronchopulmonary aspergillosis (ABPA) (4:5), which ser- 
iously complicates the course of CF lung disease and is 
difficult to diagnose, since the symptoms overlap those of 
chronic bronchopulmonary infection (4,6). 
Factors predisposing to Aspevgillus colonization remain 
unclear. Some studies suggest an association between 
increasing age, and living in a rural environment, and the 
prevalence of Aspergillus colonization (7,s). The clinical 
significance of such colonization remains controversial. 
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Several studies report that sensitization to Aspergillus in the 
presence of increased total IgE and increased antibody titre 
alone is associated with decreased lung function in CF 
patients (9,lO). Colonization alone is not suggested as a risk 
factor for more advanced lung disease in one study (9), 
whereas other publications find a correlation between 
Aspergillus colonization and severity of disease (5,ll). 
In this study, we investigated which demographic or 
clinical factors may be associated with Aspergillus coloniza- 
tion in the adult CF patients of our outpatient clinic. We 
analysed (1) the prevalence of Aspergillus colonization in 
the CF population and (2) the relationship between 
Aspergillus colonization and (a) age, (b) gender, (c) 
colonization with Pseudomonas aemginosa and Bwkholder- 
ia cepacia, and duration of this colonization, and (d) 
antibiotic therapy regimen and duration of the therapy. We 
also examined whether AspeTgillus colonization is asso- 
ciated with more advanced lung disease in these patients. 
Methods 
STUDY GROUP AND DATA ANALYSED 
All adult CF patients who attended our outpatient clinic in 
1997 were included in this study. The diagnosis of CF was 
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confirmed by positive sweat chloride tests and/or DNA 
analysis. Sputum samples were cultured as described 
elsewhere (12). Aspergillus colonization was assumed when 
Aspergillus species were found in at least two of four 
sputum samples during the 1 yr observation period. 
Patients colonized with Staphylococcus aureus received 
prophylactic oral antibiotics with anti-staphylococcal pro- 
perties continuously. In the case of Pseudomonas coloniza- 
tion, we usually recommended inhalation therapy 
beginning with tobramycin (Gernebcin@, Lilly, Stolberg, 
Germany) or, when the strain was resistant to tobramycin, 
with colistin (Colistin@, Gruenenthal, Bad Homburg, 
Germany), also continuously. The severity of CF lung 
disease was estimated by lung function investigation and 
evaluation of the Crispin-Norman score (CNS). For the 
analysis we used average values of at least the three best 
lung functions and CNS values. 
The data analysed included age, gender, lung function 
parameters, CNS values, colonization with Pseudomonas 
aeruginosa and antibiotic therapy regimen. 
STATISTICAL ANALYSIS 
All continuous variables are given as median (25-75 
percentiles) or median (range), if appropriate. Categorical 
variables are expressed as number of cases (%; 95% 
confidence interval). To compare the data, the Mann- 
Whitney test for independent non-parametric samples was 
used. Categorical variables were compared using the 
Pearson’s x2 procedure. Significance was defined as a P 
value of 10.05. 
Results 
One hundred and four CF patients (46 women) of median 
age 25 years (Table 1) were evaluated. Eleven patients had a 
history of ABPA with no recent manifestations for at least 2 
yr. The majority of patients (80.8%; Table 1) was colonized 
with Pseudomonas aeruginosa or Burkholderia cepacia, or 
with both strains. Although lung function parameters were 
normal in 17 of 104 patients (16.3%) [median (range) 
forced expiratory volume in 1 set (FEVJ 101 (Sl-129)% 
pred.], in most patients we observed airway obstruction of 
various degree, with median FEVi for the whole group of 
48.5% pred. (Table 1). When compared to Pseudomonas 
negative patients, Pseudomonas colonized patients showed 
worse lung function [FEVi 47.6 (32.7-68.9) vs. 56.3 (38- 
104)% pred. in non-colonized] and chest radiography [CNS 
12 (9-16) vs. 9 (5-12) in non-colonized; PcO.05, both 
comparisons). Colonization with Pseudomonas in these 
patients was not age- or gender-associated (P>O.3; data 
not shown). 
Repeated investigations of CF sputum samples revealed 
Aspergillus species in 43 of 104 (41.3%) patients (Tables 1 
and 2). There was no significant difference in age (P>O.4), 
gender ratio (P = 0.4), lung function (P >0.9) and CNS 
(P > 0.1) values between Aspergillus positive and negative 
patients (Table,2). With regard to colonization with 
Pseudomonas strains, we found no significant relationship 
with Aspergillus colonization. Thus, neither the prevalence 
of colonization with Pseudomonas aeruginosa or Burkhol- 
deria cepacia, nor the duration of this colonization was 
associated with a higher prevalence of Aspergillus coloniza- 
tion (P>O.5, both comparisons; Table 2). Regarding the 
sensitization to Aspergillus we correlated total serum IgE 
and results of skin prick test with Aspergillus antigen with 
Aspergillus colonization and non-colonization and could 
not find any difference between both groups (P>O-3). The 
next question we analysed concerned the relationship 
between antibiotic therapy pgimen and the prevalence of 
Aspergillus colonization. The finding that the percentage of 
patients who received prophylactic therapy with oral 
antibiotics was significantly higher in the Aspergillus 
positive group was interesting (74.4 vs. 55.7% in Aspergillus 
negative group, P = 0.05; Table 2). The association 
between antibiotic therapy and Aspergillus colonization 
was even stronger when the subgroup treated with inhaled 
TABLE 1. Demographic and clinical data of CF patients evaluated in the study 
Age, (years) 
Women 
vc, 1 
VC, % pred. 
FEVi, 1 
FEVi, % pred. 
Crispin-Norman Score 
Colonization with Pseudomonas aeruginosa, cases 
Colonization with Aspergillus species, cases 
Colonization with both species, cases 
Prophylactic antibiotic therapy: 
Oral antibiotics, cases 
Inhaled antibiotics, cases 
Both, oral and inhaled, cases 
25 (20-30) 
46 [44.2%; 23.9955.4%] 
3.1 (2.44.2) 
74.5 (55.3-87.3) 
1.8 (1.3-2.9) 
48.5 (33.2-73.7) 
11 (9-15) 
84 [SO.S%; O.l-88.4%] 
43 [41.3%; 0.2-52.5%] 
36 [34.6%] 
66 163.5%; 51.7-73.6%] 
55 [52.9%; 41.2-63.8%] 
46 [44.2%; 32.2,-56%] 
Data are expressed as median (25-75 percentiles) or cases number 1%; 95% confidence interval]. VC: vital capacity. 
ANTIBIOTIC THEARAPYAND ASPERGZLLUS IN CF 837 
TABLE 2. Data of Aspergillus positive vs. Aspergillus negative patients 
Aspergillus positive 
(n = 43) 
Aspevgillus negative 
(n = 61) 
Age (years) 
Women 
FEVi, % pred. 
Normal values, cases 
Mild obstruction, cases 
Moderate obstruction, cases 
Severe obstruction, cases 
Crispin-Norman Score 
Colonization with Pseudomonas species, cases 
Colonization with Pseudomonas species, yrs 
Continuous prophylactic therapy with: 
Oral antibiotics, cases 
Oral antibiotics, yrs 
Inhaled antibiotics, cases 
Inhaled antibiotics, yrs 
No antibiotics, cases 
Both antibiotics 
26 (21-30) 24 (20-30) 
24 [55+3%; 37-72.2%] 22 [36.1%; 48.2-771 
49.2 (33.3-71.8) 47.2 (32-77.6) 
4 [9.3%; 1.2-25.1%] 13 [21.3%; 9.P36.5%] 
12[27.9%; 12-47%] 7 111.5%; 2-24.8%] 
13 [30.2%; 13649.4%] 20 [32.8%; 18~14343%] 
14 [32.6%; 15.451.2%] 21 134.4%; 19.1-50.5%] 
12 (9-16) 11 (9-15) 
36 [83.7%; 65.3-93.5%] 49 [80.3%; 65G90%] 
9.5 (6-13) 8 (5-13) 
32 [74,4%; 55.6-87.3%]* 34 [55.7%;40-69.6%] 
8 (5-14) 10 (5.5-13.5) 
28 [65.1%;46-80%]§ 27 [44,3%; 29d-58.9%] 
5 (2.5-7.5) 5 (2-7.3) 
8 [18.6%; 6.3-36%] 21[34,4%;20-50%] 
25 [58.1%; 37.9-75%J7 21 [34,4%; 2&50%] 
Data are expressed as (25-75 percentiles) or cases number [%; 95% confidence interval]. *P= 0.05; §P= 0.036; TP = 0.048. 
The duration of prophylactic therapy with antibiotics was defined as the start of continuous medication with either oral or 
inhaled antibiotics from the beginning to the study period in years and as % of all patients, who received this continuous 
therapy. Pulmonary function was defined as follows: normal values: FEVi > 80% pred; mild obstruction FEVi; 60-80% 
pred; moderate obstruction: FEVi 40-60% pred; and severe obstruction: FEVi < 40% pred. 
antibiotics was analysed (65.1 vs. 44.3% in Aspevgillus patients only and did not compare them with data of CF 
negative group, P = 0.035; Table 2). Additionally, Asper- children. Aspergillus colonization in this study was not 
gillus positive patients received significantly more often gender-associated. In contrast to colonization with Pseu- 
antibiotics in both applications, than did Aspergillus domonas species, which was found in our and other studies 
negative patients (58.1 vs. 34,4%, respectively, P = 0.048; to be associated with worse lung disease, Aspergillus 
Table 2). recovery did not relate to more advanced lung disease. 
Discussion 
The role of Aspergillus species in the pathogenesis of CF 
lung disease is still not clear. The data on the prevalence of 
Aspergillus colonization in CF, and the course of lung 
disease after being colonized, are rare and vary from centre 
to centre. In this study, we analysed data of 104 adult CF 
patients of our outpatient clinic in order to evaluate the 
prevalence of Aspergillus colonization, and to reveal factors 
which may be associated with this colonization. Age of the 
patients, gender, colonization with Pseudomonas aeruginosa 
or Burklzolderia cepacia, severity of CF lung disease and 
therapy regimen were analysed with regard to Aspergillus 
colonization. 
Our data about the prevalence of Aspergihs coloniza- 
tion in adult CF patients (41.3%) are in a good agreement 
with data reported in literature (l-3; 11,13,14). In contrast 
to previous investigations (7), we did not find any 
relationship between age of the patients and the prevalence 
of Aspergillus recovery. This fact may be explained through 
differing study groups: we evaluated data of adult CF 
The most striking finding of this study was the significant 
relationship between prophylactic antibiotic therapy and 
Aspergillus colonization. This relationship was true for oral 
(P = 0.05) and inhaled antibiotics (P = 0,036) and their 
combination (P = 0.048). The use of prophylactic anti- 
biotics is an established therapy to improve lung function 
and has been shown to reduce the frequency of exacerba- 
tions, to slow the progress of CF lung disease and to 
improve lung function (15,16,17). Until now, antibiotic 
therapy is believed to rarely induce side effects, and a 
majority of CF patients uses inhaled or oral antibiotics for 
many years. Our data may lead to concerns about the side 
effects of such therapy unknown thus far. To explain these 
findings, the following can be suggested: firstly, antibiotics 
can change the natural milieu of mucosal surfaces and 
therefore predispose to fungal infection. The increased 
prevalence of Aspergillus colonization as a side effect of a 
long-term antibiotic therapy of CF patients would not then 
be surprising, although not yet reported. Another possible 
explanation arises from the observation, that Pseudomonas 
and Aspergillus species function as antagonists, and 
Pseudomonas species have been reported to suppress fungal 
growth in culture (18). It is therefore tempting to postulate, 
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that complete or incomplete eradication of Pseudomonas in 
CF airways due to the inhalation of antibiotics could alter 
the counterbalance between Pseudomonas and Aspergillus 
species, and thus facilitate the fungal infection. Since the 
data about the association between Aspergillus colonization 
and more rapid lung disease are controversial (5,9, and our 
data) the clinical relevance of this observation remains 
unclear. Some in vitro data, however, suggest that 
Aspergillus causes damage to human respiratory epithelium 
(19). Nonetheless, the benefit of prophylactic therapy 
should not be questioned at this point. Further prospective 
studies have to confirm our results, since our retrospective 
analysis precluded randomization and ‘confounding by 
indication’ cannot be completely excluded. 
In conclusion, our data indicate that prophylactic 
antibiotic therapy with inhaled and, possibly, oral anti- 
biotics may predispose CF patients to Aspergillus coloniza- 
tion. Further observations are necessary to evaluate the 
clinical significance of this colonization in CF patients. 
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